BMS-986263 is a Antisense RNAi Oligonucleotide owned by Bristol-Myers Squibb, and is involved in 10 clinical trials, of which 9 were completed, and 1 is ongoing.

BMS-986263 (ND-L02-s0201) is a vitamin A–coupled liposomes which deliver siRNA against a collagen-specific chaperone heat shock protein 47 (HSP47). The drug candidate causes gene knockdown of a Hsp47 in fibrogenic cells. HSP47 siRNA suppresses collagen expression and macrophage infiltration, thereby preventing fibrosis. The drug candidate decreases levels of HSP47 in fibrotic diseases that limit the excessive assembly and intracellular processing of procollagen molecules, thereby reducing accumulation of collagens to delay the progression of fibrotic diseases.

The revenue for BMS-986263 is expected to reach a total of $68m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the BMS-986263 NPV Report.

BMS-986263 was originated by Nitto BioPharma and is currently owned by Bristol-Myers Squibb.

BMS-986263 Overview

BMS-986263 (ND-L02-s0201) is under development for the treatment of non-alcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis and cirrhosis secondary to non-alcoholic steatohepatitis (NASH) and hepatitis C. The drug candidate is administered through intravenous route. It is a vitamin A-coupled lipid nanoparticle (LNP) containing siRNA against heat shock protein 47 (HSP47). The drug candidate is based on siRNA technology.

Bristol-Myers Squibb Overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

The company reported revenues of (US Dollars) US$46,385 million for the fiscal year ended December 2021 (FY2021), an increase of 9.1% over FY2020. The operating profit of the company was US$8,615 million in FY2021, compared to an operating loss of US$6,847 million in FY2020. The net profit of the company was US$6,994 million in FY2021, compared to a net loss of US$9,015 million in FY2020. The company reported revenues of US$11,218 million for the third quarter ended September 2022, a decrease of 5.6% over the previous quarter.

Quick View – BMS-986263

Report Segments
  • Innovator
Drug Name
  • BMS-986263
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Gastrointestinal
  • Respiratory
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.